MedPage Today: “Barely one-quarter of patients with cancer obtained protection against COVID-19 after one dose of the Pfizer/BioNTech vaccine, a prospective study showed.
The data found a “strikingly low” 28% immune efficacy rate in patients with cancer, including 13% in patients with blood cancers. In contrast, first-dose seroconversion occurred in 97% of a healthy control group, Adrian Hayday, PhD, of King’s College London, and co-authors concluded in a report posted to the preprint server medRxiv.
A second dose at day 21, however, brought adequate immunity to nearly all the cancer patients, they said.”
Read more Read more here